M1 KLINIKEN AG (M12.DE) Fundamental Analysis & Valuation

FRA:M12 • DE000A0STSQ8

Current stock price

15 EUR
0 (0%)
Last:

This M12.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

6

1. M12.DE Profitability Analysis

1.1 Basic Checks

  • M12 had positive earnings in the past year.
  • In the past year M12 had a positive cash flow from operations.
  • In the past 5 years M12 has always been profitable.
  • Each year in the past 5 years M12 had a positive operating cash flow.
M12.DE Yearly Net Income VS EBIT VS OCF VS FCFM12.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M 20M 30M

1.2 Ratios

  • M12's Return On Assets of 8.73% is amongst the best of the industry. M12 outperforms 96.43% of its industry peers.
  • Looking at the Return On Equity, with a value of 15.03%, M12 belongs to the top of the industry, outperforming 85.71% of the companies in the same industry.
  • Looking at the Return On Invested Capital, with a value of 13.44%, M12 belongs to the top of the industry, outperforming 92.86% of the companies in the same industry.
  • M12 had an Average Return On Invested Capital over the past 3 years of 7.72%. This is in line with the industry average of 6.23%.
  • The 3 year average ROIC (7.72%) for M12 is below the current ROIC(13.44%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 8.73%
ROE 15.03%
ROIC 13.44%
ROA(3y)5.18%
ROA(5y)4.73%
ROE(3y)9.59%
ROE(5y)9.22%
ROIC(3y)7.72%
ROIC(5y)6.16%
M12.DE Yearly ROA, ROE, ROICM12.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 5 10 15

1.3 Margins

  • M12 has a better Profit Margin (5.00%) than 75.00% of its industry peers.
  • M12's Profit Margin has declined in the last couple of years.
  • With a decent Operating Margin value of 8.52%, M12 is doing good in the industry, outperforming 71.43% of the companies in the same industry.
  • M12's Operating Margin has declined in the last couple of years.
  • Looking at the Gross Margin, with a value of 19.29%, M12 is doing worse than 60.71% of the companies in the same industry.
  • In the last couple of years the Gross Margin of M12 has declined.
Industry RankSector Rank
OM 8.52%
PM (TTM) 5%
GM 19.29%
OM growth 3Y27.08%
OM growth 5Y-5.31%
PM growth 3Y18.61%
PM growth 5Y-17.82%
GM growth 3Y2.18%
GM growth 5Y-14.45%
M12.DE Yearly Profit, Operating, Gross MarginsM12.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30 40

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. M12.DE Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), M12 is creating value.
  • M12 has less shares outstanding than it did 1 year ago.
  • The number of shares outstanding for M12 has been increased compared to 5 years ago.
  • Compared to 1 year ago, M12 has a worse debt to assets ratio.
M12.DE Yearly Shares OutstandingM12.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
M12.DE Yearly Total Debt VS Total AssetsM12.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

  • M12 has an Altman-Z score of 5.29. This indicates that M12 is financially healthy and has little risk of bankruptcy at the moment.
  • The Altman-Z score of M12 (5.29) is better than 96.43% of its industry peers.
  • M12 has a debt to FCF ratio of 0.70. This is a very positive value and a sign of high solvency as it would only need 0.70 years to pay back of all of its debts.
  • M12's Debt to FCF ratio of 0.70 is amongst the best of the industry. M12 outperforms 100.00% of its industry peers.
  • A Debt/Equity ratio of 0.05 indicates that M12 is not too dependend on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 0.05, M12 belongs to the top of the industry, outperforming 96.43% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF 0.7
Altman-Z 5.29
ROIC/WACC1.81
WACC7.42%
M12.DE Yearly LT Debt VS Equity VS FCFM12.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M 60M 80M 100M

2.3 Liquidity

  • M12 has a Current Ratio of 2.06. This indicates that M12 is financially healthy and has no problem in meeting its short term obligations.
  • With an excellent Current ratio value of 2.06, M12 belongs to the best of the industry, outperforming 89.29% of the companies in the same industry.
  • M12 has a Quick Ratio of 1.35. This is a normal value and indicates that M12 is financially healthy and should not expect problems in meeting its short term obligations.
  • With a decent Quick ratio value of 1.35, M12 is doing good in the industry, outperforming 78.57% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.06
Quick Ratio 1.35
M12.DE Yearly Current Assets VS Current LiabilitesM12.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. M12.DE Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an nice 10.36% over the past year.
  • M12 shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 7.97% yearly.
  • The Revenue has been growing slightly by 6.52% in the past year.
  • Measured over the past years, M12 shows a very strong growth in Revenue. The Revenue has been growing by 34.44% on average per year.
EPS 1Y (TTM)10.36%
EPS 3Y21.62%
EPS 5Y7.97%
EPS Q2Q%25%
Revenue 1Y (TTM)6.52%
Revenue growth 3Y2.54%
Revenue growth 5Y34.44%
Sales Q2Q%9.42%

3.2 Future

  • M12 is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.27% yearly.
  • M12 is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 8.24% yearly.
EPS Next Y9.46%
EPS Next 2Y12.44%
EPS Next 3Y12.27%
EPS Next 5YN/A
Revenue Next Year5.17%
Revenue Next 2Y6.28%
Revenue Next 3Y6.07%
Revenue Next 5Y8.24%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
M12.DE Yearly Revenue VS EstimatesM12.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M 500M
M12.DE Yearly EPS VS EstimatesM12.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0.2 0.4 0.6 0.8 1

More info and screens

Find the best growth stocksShow best growing peers

5

4. M12.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 15.96 indicates a correct valuation of M12.
  • Based on the Price/Earnings ratio, M12 is valued a bit cheaper than 60.71% of the companies in the same industry.
  • M12 is valuated rather cheaply when we compare the Price/Earnings ratio to 27.95, which is the current average of the S&P500 Index.
  • A Price/Forward Earnings ratio of 13.47 indicates a correct valuation of M12.
  • Based on the Price/Forward Earnings ratio, M12 is valued a bit cheaper than the industry average as 64.29% of the companies are valued more expensively.
  • The average S&P500 Price/Forward Earnings ratio is at 38.68. M12 is valued rather cheaply when compared to this.
Industry RankSector Rank
PE 15.96
Fwd PE 13.47
M12.DE Price Earnings VS Forward Price EarningsM12.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • M12's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. M12 is cheaper than 67.86% of the companies in the same industry.
  • The rest of the industry has a similar Price/Free Cash Flow ratio as M12.
Industry RankSector Rank
P/FCF 11.03
EV/EBITDA 7.2
M12.DE Per share dataM12.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

  • M12's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
  • The decent profitability rating of M12 may justify a higher PE ratio.
  • M12's earnings are expected to grow with 12.27% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.69
PEG (5Y)2
EPS Next 2Y12.44%
EPS Next 3Y12.27%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

4

5. M12.DE Dividend Analysis

5.1 Amount

  • With a Yearly Dividend Yield of 3.33%, M12 has a reasonable but not impressive dividend return.
  • M12's Dividend Yield is rather good when compared to the industry average which is at 1.84. M12 pays more dividend than 89.29% of the companies in the same industry.
  • Compared to an average S&P500 Dividend Yield of 1.81, M12 pays a better dividend.
Industry RankSector Rank
Dividend Yield 3.33%

5.2 History

Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years1
M12.DE Yearly Dividends per shareM12.DE Yearly Dividends per shareYearly Dividends per share 2018 2019 2024 2025 0.1 0.2 0.3 0.4

5.3 Sustainability

DPN/A
EPS Next 2Y12.44%
EPS Next 3Y12.27%
M12.DE Yearly Income VS Free CF VS DividendM12.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M 20M

More info and screens

Find the best dividend stocksShow peers with best dividend

M12.DE Fundamentals: All Metrics, Ratios and Statistics

M1 KLINIKEN AG

FRA:M12 (4/17/2026, 7:00:00 PM)

15

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)11-18
Earnings (Next)04-22
Inst Owners1.07%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap294.60M
Revenue(TTM)354.98M
Net Income(TTM)17.74M
Analysts85.71
Price Target28.05 (87%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 3.33%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)4.06%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.87%
Valuation
Industry RankSector Rank
PE 15.96
Fwd PE 13.47
P/S 0.83
P/FCF 11.03
P/OCF 10.89
P/B 2.5
P/tB 10.73
EV/EBITDA 7.2
EPS(TTM)0.94
EY6.27%
EPS(NY)1.11
Fwd EY7.42%
FCF(TTM)1.36
FCFY9.06%
OCF(TTM)1.38
OCFY9.18%
SpS18.07
BVpS6.01
TBVpS1.4
PEG (NY)1.69
PEG (5Y)2
Graham Number11.2725 (-24.85%)
Profitability
Industry RankSector Rank
ROA 8.73%
ROE 15.03%
ROCE 19.39%
ROIC 13.44%
ROICexc 18.99%
ROICexgc 105.66%
OM 8.52%
PM (TTM) 5%
GM 19.29%
FCFM 7.52%
ROA(3y)5.18%
ROA(5y)4.73%
ROE(3y)9.59%
ROE(5y)9.22%
ROIC(3y)7.72%
ROIC(5y)6.16%
ROICexc(3y)9.69%
ROICexc(5y)8.26%
ROICexgc(3y)31.7%
ROICexgc(5y)24.88%
ROCE(3y)11.15%
ROCE(5y)8.88%
ROICexgc growth 3Y38.16%
ROICexgc growth 5Y31.27%
ROICexc growth 3Y22.22%
ROICexc growth 5Y5.12%
OM growth 3Y27.08%
OM growth 5Y-5.31%
PM growth 3Y18.61%
PM growth 5Y-17.82%
GM growth 3Y2.18%
GM growth 5Y-14.45%
F-Score9
Asset Turnover1.75
Health
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF 0.7
Debt/EBITDA 0.17
Cap/Depr 6.62%
Cap/Sales 0.1%
Interest Coverage 21.13
Cash Conversion 76.34%
Profit Quality 150.51%
Current Ratio 2.06
Quick Ratio 1.35
Altman-Z 5.29
F-Score9
WACC7.42%
ROIC/WACC1.81
Cap/Depr(3y)22.84%
Cap/Depr(5y)24.89%
Cap/Sales(3y)0.41%
Cap/Sales(5y)0.51%
Profit Quality(3y)272.44%
Profit Quality(5y)207.18%
High Growth Momentum
Growth
EPS 1Y (TTM)10.36%
EPS 3Y21.62%
EPS 5Y7.97%
EPS Q2Q%25%
EPS Next Y9.46%
EPS Next 2Y12.44%
EPS Next 3Y12.27%
EPS Next 5YN/A
Revenue 1Y (TTM)6.52%
Revenue growth 3Y2.54%
Revenue growth 5Y34.44%
Sales Q2Q%9.42%
Revenue Next Year5.17%
Revenue Next 2Y6.28%
Revenue Next 3Y6.07%
Revenue Next 5Y8.24%
EBIT growth 1Y32.15%
EBIT growth 3Y30.31%
EBIT growth 5Y27.31%
EBIT Next Year39.44%
EBIT Next 3Y18.54%
EBIT Next 5YN/A
FCF growth 1Y132.58%
FCF growth 3Y27.23%
FCF growth 5YN/A
OCF growth 1Y108.94%
OCF growth 3Y24.88%
OCF growth 5YN/A

M1 KLINIKEN AG / M12.DE Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for M1 KLINIKEN AG?

ChartMill assigns a fundamental rating of 6 / 10 to M12.DE.


What is the valuation status for M12 stock?

ChartMill assigns a valuation rating of 5 / 10 to M1 KLINIKEN AG (M12.DE). This can be considered as Fairly Valued.


Can you provide the profitability details for M1 KLINIKEN AG?

M1 KLINIKEN AG (M12.DE) has a profitability rating of 6 / 10.


Can you provide the expected EPS growth for M12 stock?

The Earnings per Share (EPS) of M1 KLINIKEN AG (M12.DE) is expected to grow by 9.46% in the next year.